How CellDecide evaluates regenerative medicine claims.

Why this methodology exists

Regenerative medicine moves faster than most patients can track. The same biologic — a cell type, a growth-factor concentrate, an exosome preparation — may be unavailable in one country, offered at a major hospital under ministry authorization in another, and enrolled in a registered clinical trial somewhere else. The science underneath is identical; the regulatory and clinical contexts are not. Reading those contexts accurately is the first job of this site.

This page is the standard every other page on CellDecidefollows. It defines how we describe a treatment, how we separate the questions a patient should actually ask, and how we keep optimism — which we genuinely have — from drifting into anything that looks like a sales pitch. The science here is interesting. We will say so. We will also keep the categories straight, so that “interesting” does not get mistaken for “proven.”

We do not read the world through a single regulator. The U.S. Food & Drug Administration matters, especially for U.S. readers, and we will always state FDA status plainly. It is also one regulator among many. Japan, South Korea, Thailand, China, Mexico, Panama, and other countries operate their own pathways for regenerative care, with different timelines, different evidence requirements, and different definitions of what counts as approved, conditional, or investigational. Flattening that into a U.S.-only picture loses information patients need.

Our global regulatory lens

Every regenerative procedure sits inside a stack of approvals, exemptions, and clinical-use pathways. That stack does not always line up across borders. On every page that names a specific intervention, we describe each layer of the stack separately, so the reader can see exactly which questions a given authorization does — and does not — answer.

For each named treatment, we record

• U.S. FDA status for the specific indication — approved, investigational under an IND, unapproved, or marketed outside a cleared label.
• Local regulatory status in the treatment country — full approval, conditional approval, hospital exemption, compassionate-use route, clinical-use license, registered trial, or a private offering outside any of the above.
• Setting — tertiary hospital, accredited outpatient clinic, research center, or commercial clinic.
• Oversight — institutional review board, ethics committee, ministry of health, or none stated.
• Trial registration — listed on ClinicalTrials.gov, the EU Clinical Trials Register, the WHO ICTRP, or a national registry — and the actual phase + status.
• Indication match — whether the authorization covers the specific condition being marketed, or a different one.

Our evidence ladder

Not all evidence is the same kind of evidence. A petri dish is not a patient, a rat is not a person, and a forty-patient uncontrolled series is not a randomized trial. We use a nine-rung ladder when we describe what is actually known about a regenerative therapy for a specific condition.

1. Biological plausibility. The proposed mechanism is consistent with what is known about the cell type, signaling pathway, or tissue biology. Plausibility is a starting question, not an answer.
2. Lab and preclinical evidence. In-vitro or bench-top data — cells, tissues, organoids. Suggestive of a signal, not evidence of clinical benefit.
3. Animal-model data. Effects observed in vivo in another species. Translates to humans inconsistently and often does not.
4. Case reports and patient-reported outcomes. Individual stories. Useful as hypothesis generators; not evidence of population-level efficacy.
5. Case series and registry data. Patterns across many patients, but without a comparison group. Vulnerable to selection bias and placebo response.
6. Small human studies. Pilot trials, single-arm or small randomized, often unblinded. A real signal, but imprecise and easily overturned at scale.
7. Adequately powered randomized controlled trials. Sufficient sample size, ideally blinded and sham-controlled. The first rung at which efficacy can be claimed with confidence for a specific use.
8. Systematic reviews and clinical guidelines. Aggregated trial evidence, formally graded for certainty, by an independent body.
9. Regulatory approval for the specific indication. A regulator — U.S. or otherwise — has authorized a specific use under that jurisdiction's standard. The label, conditions, and evidence threshold still matter: approvals can be full, conditional, time-limited, hospital-exempt, or accelerated, and we name which kind on every page.

Evidence is condition-specific. A therapy studied for knee osteoarthritis does not automatically transfer to spinal cord injury, autism, COPD, cosmetic anti-aging outcomes, or neurodegenerative disease. When we describe what is known about a treatment, we describe it for the specific indication and the specific protocol — not for the cell type as a category. Most real-world disagreement about regenerative medicine collapses the moment indications are named precisely.

What we score separately

A treatment is never one number. We score eight dimensions independently on every page that names a specific procedure, because they move on their own — a treatment can be strong on science and weak on follow-up; strong on regulatory pathway and thin on outcome data; strong on institutional setting and silent on cost. Collapsing those into a single rating hides exactly the information a patient needs.

• Science. What human evidence exists for this specific indication, at what rung of the evidence ladder?
• Regulation. Where is it approved, conditionally permitted, investigational, or unregulated? We name jurisdictions; we do not generalize.
• Procedure. What cell or biologic, from what source, processed how, delivered through what route, at what dose, on what schedule?
• Provider. Who delivers it, with what credentials, at what kind of institution, under what oversight?
• Safety. What adverse events have been reported in the literature or by regulators, at what frequency, and what is the realistic risk profile?
• Practical burden. Total cost, travel time, repeat visits, recovery window, follow-up requirements, downstream care.
• Alternatives. Standard care for the same condition. Registered trials. Physical therapy, medication, surgery, watchful waiting. We name them; we do not assume the reader has already considered them.
• Conflicts. Anything that could distort the page — referral compensation, sponsorship, affiliate relationships, sponsored access.

How we talk about FDA status

FDA status matters. It is also not the only thing that matters. We will always state it plainly for U.S. readers; we will not let it become the only frame.

• For U.S. readers, FDA status is decision-relevant. It determines what a U.S. clinician can administer under standard of care, whether insurance is likely to cover it, and which products carry an externally reviewed efficacy record in this country.
• The FDA-approved regenerative-medicine category in the U.S. is narrow. Hematopoietic stem-cell products from cord blood for specific blood and immune disorders, and a small number of approved cell and gene therapies, are the headline of that list — not the whole regenerative-medicine field.
• Many regenerative products marketed in the U.S. are not FDA-approved for the uses being advertised. That applies to common direct-to-consumer offerings — mesenchymal stromal cells, exosomes, amniotic and Wharton's jelly products, adipose-derived preparations — when they are administered outside a registered trial for indications they are not labeled for. It is a fact about U.S. enforcement and labeling, not a global verdict on the underlying biology.
• A ClinicalTrials.gov listing is not an FDA approval. It is a registration document for a study still being conducted. A listing is not an endorsement, not evidence of efficacy, and not proof of safety on its own. The trial is being run because those things are not yet known.
• FDA non-approval does not automatically mean a treatment is worthless. It may mean the company has not filed; the trial pipeline is not mature; the use is outside the cleared label; or the evidence base has not been generated under U.S. regulatory expectations. The right reading is “evidence still developing,” not “rejected.”

We state the FDA answer, and we state the global answer. Both belong on the page.

How we talk about treatments abroad

Patients travel abroad for regenerative medicine for sober, common reasons. Some procedures are offered sooner in other regulatory systems. Some are hospital-based at tertiary medical centers in countries with national health-ministry oversight. Some are available at meaningfully lower cost. Some include longer in-country follow-up than U.S. equivalents. Travel is not by itself evidence of desperation, and it is not by itself evidence of recklessness.

Other countries operate their own regulatory pathways for regenerative care. Pathway categories we expect to encounter and verify per page include — for example — Japan's conditional-approval route, South Korea's biopharmaceutical review, Thailand's hospital and ministry-licensed protocols, China's hospital-exception and trial routes, and various clinic and hospital programs in Mexico, Panama, and elsewhere. These are categories to verify, not blanket endorsements of every offering in those jurisdictions: each treatment or destination page names the specific pathway in use, links the primary source, and checks whether that pathway actually covers the indication being marketed. Reading the world through a U.S.-only lens flattens information patients need; treating “available abroad” as a single category flattens it back the other way.

Permitted in one jurisdiction, investigational in another. That is the actual map. The questions we always ask — and that any patient should ask before paying — are:

• Which regulatory body permits this here? National health ministry, hospital exemption, compassionate-use route, clinical-use license, active trial protocol, or a private clinic operating outside ministry oversight? The label matters; the answer is not always the same as the marketing implies.
• Is the institution licensed for this specific procedure? Hospital accreditation in general — JCI, national licensing — is not the same as authorization for a specific regenerative protocol.
• What is the cell source?Autologous (from you), allogeneic (donor-derived), perinatal (cord blood, cord tissue, placental, Wharton's jelly), or fetal? Each carries its own regulatory, biological, and ethical profile.
• How is the product processed? Minimally manipulated or substantially manipulated? In a registered manufacturing facility, a hospital pharmacy, or in-clinic? Processing changes the regulatory classification in most jurisdictions.
• What sterility, identity, and potency testing is performed? Documentation should exist and be available to the patient.
• What adverse-event reporting and post-treatment follow-up is in place? Both at the local clinic and for patients who fly home.
• What is the plan if a complication occurs after you leave the country? This is the question patients ask least and need most.
• What does the consent document actually say? Specifically about what is “investigational,” what is “off-label,” what is offered as commercial care, and what outcome is realistically expected.

How we review clinics and hospitals

CellDecide does not currently recommend specific clinics or hospitals. When we eventually publish institutional reviews — and we expect to — the framework below is the standard we will apply to every provider in every country, with the same set of questions, in the same order, regardless of marketing budget, destination, or referral relationship.

• Physician credentials and specialty fit. Trained for this body system, this condition, this procedure — not adjacent.
• Institutional licensing. Hospital accreditation, clinic licensing, and pathway-specific authorization where applicable. The license should match the procedure.
• Local regulatory pathway, named precisely. Approved use, hospital exemption, clinical-use license, ethics-board protocol, registered trial, or commercial offering.
• Cell and biologic source. Documented, traceable, with manufacturing standards we can read.
• Processing and laboratory standards. Sterility, identity, and potency testing. In-house or contract manufacturing. GMP equivalent or not.
• Informed-consent quality. Does the consent document distinguish investigational from approved? Does it state what is and is not known? Does it list realistic risks without burying them?
• Claim-versus-evidence alignment.Does the clinic's public marketing match what its consent document says? Does either match the underlying literature?
• Pricing transparency. Total cost, what is included, what is extra, and the cost path if the first treatment does not produce the expected outcome.
• Pre-travel screening. Eligibility criteria, contraindications, and what conditions are explicitly declined. A clinic that accepts every patient is itself a signal.
• Follow-up protocol. What happens at 30, 90, 180, and 365 days. Who is responsible. What is in writing.
• Complication and adverse-event plan. Specific, not generic. Named contacts. A defined escalation path.
• Outcomes tracking. Whether the institution publishes its own outcome data, and whether anyone independent has reviewed it.
• Regulatory transparency. Whether the clinic clearly explains its U.S. FDA status and its local regulatory pathway, in language a non-clinician can verify.

How we handle optimism and uncertainty

Two readings of regenerative medicine both pass the smell test. The first reads the field as one of the genuinely interesting frontiers in modern medicine — a place where cell biology, immunology, and surgical practice intersect, where new approvals continue to land, and where conditions that had no real options are beginning to. The second reads the field as a marketing landscape that has, for a long time, outrun the evidence — where clinics in many countries sell hope at high prices to patients who do not have time to wait.

Both readings are accurate. CellDecide holds both at once. That is the editorial discipline, and it is not a contradiction.

We believe regenerative medicine may become one of the defining medical fields of the coming decades. We do not believe hope is the same as proof. The work of this site is to keep both visible — the possibility that the field is early and important, and the discipline to ask what is actually known.

Phrases we use on treatment pages

• early but plausible
• available abroad, evidence still developing
• permitted in one jurisdiction, investigational in another
• hospital-based, but still condition-specific
• promising signal, not settled science
• lack of disproof is not the same as proof
• worth discussing with a qualified physician

These are not hedges. They are accurate descriptions of where a specific treatment sits. When the evidence base for a treatment moves up the ladder, the language on the page moves with it.

Medical tourism standards

Traveling for care is a real decision with a real timeline and real risk. The bar is higher than picking a vacation. Before booking a flight for a regenerative procedure, the checklist below is what we believe every patient should walk through — with their home-country physician, not with the clinic that is selling the treatment.

• Confirm the diagnosis at home. A second-opinion workup with a home-country specialist before traveling — not after.
• Confirm eligibility against the clinic's own published criteria. Some clinics decline patients abroad after travel; learn that early.
• Plan the travel risk. Long-haul flying, time-zone-shifted recovery, language access during emergencies, companion support.
• Have a complication plan. What happens on day 4 abroad? Day 30 at home? Day 90? Who do you call. Have the phone numbers written down.
• Identify a home-country physician for follow-up before you leave. Not after.
• Move your records both directions. Hospital release before travel; full discharge summary, lab reports, imaging, and procedure report to take home.
• Total cost, not just procedure cost. Travel, lodging, companion, time off work, repeat visits, complication contingency. Get the full number before paying the deposit.
• Language and consent. Are the consent documents available in your reading language? Have you actually read them?
• Insurance and legal expectations. Many U.S. and home-country insurance plans do not cover overseas regenerative procedures, including complications. Understand that before paying.
• Standard care continuity.Do not stop current treatment without a clinician's input. Adding a regenerative procedure abroad is a different decision from replacing standard care, and the difference matters.

Conflicts, referrals, and money

CellDecide is independent and is not currently a referral service. That may change. If it does, the relationship will be visible — at the point of recommendation, before any link to a clinic or program, in plain language a reader cannot miss.

If CellDecide receives referral fees, sponsorships, affiliate compensation, or clinic payments, that relationship will be disclosed near every recommendation it touches. Compensation will not determine evidence ratings, regulatory summaries, safety warnings, or whether uncertainty is shown on the page.

Readers should still make medical decisions with a licensed clinician, not with us. Our job is to organize the questions and the sources. The decision is yours, with your physician.

What we will not do

There are things we will not do, regardless of pressure or business case.

• We will not call a therapy proven because it is popular abroad.
• We will not call a therapy useless because it is not FDA-approved.
• We will not treat testimonials as clinical proof.
• We will not present medical tourism as risk-free.
• We will not use “cure,” “guaranteed,” “miracle,” or “permanently regenerate” in the language of this site.
• We will not call a treatment “safe” or “effective” in general — only for a specific indication, sourced to a specific study or approval.
• We will not hide a conflict of interest.
• We will not give personal medical advice.
• We will not tell readers to stop standard care.
• We will not argue that regulators in any country are conspiring against patients. Different regulatory systems make different tradeoffs; that is reportable, not conspiratorial.
• We will not pretend the science is settled in either direction when it is not.

Sources and update policy

We work from primary sources first. When a fact appears on this site, the footnote points at the original document — not a summary, not a press release, not a clinic's reading of the source. The categories of source we treat as primary are:

• U.S. Food & Drug Administration — consumer information, approval database, warning letters, guidance documents.
• NIH and ClinicalTrials.gov — federal research and the trial registry. Registration is not endorsement.
• PubMed-indexed peer-reviewed studies — with attention to study design, sample size, blinding, and comparator.
• Professional-society guidance — ISSCR for stem-cell clinical translation, ASGCT, AAOS, IFATS, and comparable specialty societies in other countries.
• Cochrane Library and systematic reviews — graded for certainty, with the grade reported on the page.
• Local regulator and ministry documentation— including Japan's PMDA, South Korea's MFDS, Thailand's FDA and Ministry of Public Health, China's NMPA, Mexico's COFEPRIS, Panama's MINSA, and others — named on the relevant page, in the relevant language where possible.
• Institutional documentation— when a page concerns a specific hospital or clinic, the institution's own published protocol, licensing, and outcome data.
• Registered-trial protocols and results data — read together; a protocol without results is half the story.

Every page on CellDecideshows a last-updated date. Pages about regulatory status, clinic offerings, and trial data are revisited because those facts move — a Japanese conditional approval can become full approval, a U.S. enforcement action can change a clinic's standing, a Phase III readout can move a treatment up or down the evidence ladder. When the underlying source updates, the page updates and the footnote is re-verified.

If a page on this site is out of date, or a citation does not match its source, or a regulatory summary no longer reflects the current pathway — tell us. We treat substantiated corrections as priority work.

Related

• How CellDecide weighs evidence — a plain-English reading guide to lab studies, early human trials, controlled trials, and approvals.
• Sources — the primary regulators and scientific bodies we read.
• Medical-review policy — what review happens before publication, and what clinical review is not yet live.
• About — who runs this site.
• Disclosures — affiliate, advertising, and editorial-independence statements.
• Contact — corrections, source challenges, and editorial questions.